QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   83.00 (+4.34%)
AMD   119.47 (+1.07%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (-0.01%)
GE   104.67 (+3.09%)
DIS   88.59 (+0.72%)
AMC   4.55 (+1.11%)
PFE   38.02 (+0.00%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   83.00 (+4.34%)
AMD   119.47 (+1.07%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (-0.01%)
GE   104.67 (+3.09%)
DIS   88.59 (+0.72%)
AMC   4.55 (+1.11%)
PFE   38.02 (+0.00%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   83.00 (+4.34%)
AMD   119.47 (+1.07%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (-0.01%)
GE   104.67 (+3.09%)
DIS   88.59 (+0.72%)
AMC   4.55 (+1.11%)
PFE   38.02 (+0.00%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   83.00 (+4.34%)
AMD   119.47 (+1.07%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (-0.01%)
GE   104.67 (+3.09%)
DIS   88.59 (+0.72%)
AMC   4.55 (+1.11%)
PFE   38.02 (+0.00%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NASDAQ:ORGS

Orgenesis (ORGS) Competitors

$1.14
-0.05 (-4.20%)
(As of 05:11 PM ET)
Compare
Today's Range
$1.14
$1.20
50-Day Range
$1.01
$1.42
52-Week Range
$0.98
$2.70
Volume
19,304 shs
Average Volume
59,340 shs
Market Capitalization
$32.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

ORGS vs. ACXP, STSA, NOVN, PPBT, RMTI, NERV, CKPT, FLGC, YMTX, and NLTX

Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Acurx Pharmaceuticals (ACXP), Satsuma Pharmaceuticals (STSA), Novan (NOVN), Purple Biotech (PPBT), Rockwell Medical (RMTI), Minerva Neurosciences (NERV), Checkpoint Therapeutics (CKPT), Flora Growth (FLGC), Yumanity Therapeutics (YMTX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.

Orgenesis vs.

Orgenesis (NASDAQ:ORGS) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.

Acurx Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -35.18%. Orgenesis' return on equity of -41.99% beat Acurx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Orgenesis -35.18% -41.99% -15.89%
Acurx Pharmaceuticals N/A -158.17% -133.39%

Orgenesis has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -0.89, meaning that its stock price is 189% less volatile than the S&P 500.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Orgenesis. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$36.03 million0.90-$14.89 million-$0.50-2.28
Acurx PharmaceuticalsN/AN/A-$12.09 million-$1.11-2.66

Acurx Pharmaceuticals received 4 more outperform votes than Orgenesis when rated by MarketBeat users.

CompanyUnderperformOutperform
OrgenesisOutperform Votes
1
100.00%
Underperform Votes
No Votes
Acurx PharmaceuticalsOutperform Votes
5
100.00%
Underperform Votes
No Votes

Orgenesis presently has a consensus price target of $6.00, indicating a potential upside of 412.82%. Acurx Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 374.58%. Given Orgenesis' higher probable upside, equities analysts plainly believe Orgenesis is more favorable than Acurx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Acurx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Orgenesis and Orgenesis both had 1 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 0.75 beat Orgenesis' score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Orgenesis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Acurx Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

16.8% of Orgenesis shares are held by institutional investors. Comparatively, 13.1% of Acurx Pharmaceuticals shares are held by institutional investors. 7.1% of Orgenesis shares are held by company insiders. Comparatively, 30.9% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Orgenesis beats Acurx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORGS vs. The Competition

MetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$32.31M$5.81B$4.54B$6.21B
Dividend YieldN/A2.74%2.42%6.15%
P/E Ratio-2.284.6498.0611.77
Price / Sales0.90325.823,619.7395.69
Price / CashN/A20.1190.91108.26
Price / Book1.125.425.157.26
Net Income-$14.89M$189.83M$117.60M$193.48M
7 Day Performance-3.39%8.12%3.20%2.62%
1 Month Performance6.54%7.79%3.12%3.09%
1 Year Performance-55.98%23.70%23.09%1.72%

Orgenesis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACXP
Acurx Pharmaceuticals
2.2004 of 5 stars
$2.98
-0.7%
$14.00
+369.8%
+15.2%$34.78MN/A-2.683Short Interest ↓
Gap Up
STSA
Satsuma Pharmaceuticals
2.5787 of 5 stars
$1.04
-2.8%
$7.40
+611.5%
-67.4%$34.48MN/A-0.5221
NOVN
Novan
1.6894 of 5 stars
$1.22
+4.3%
$12.33
+910.9%
-47.3%$34.17M$23.68M-0.9229Analyst Downgrade
News Coverage
Gap Down
PPBT
Purple Biotech
1.941 of 5 stars
$1.95
-0.5%
$9.00
+361.5%
-38.9%$36.04M$1M-1.8619Gap Down
RMTI
Rockwell Medical
2.4716 of 5 stars
$2.63
+2.3%
$7.00
+166.2%
+102.4%$36.14M$72.81M-2.09300Analyst Report
Analyst Revision
News Coverage
Gap Up
NERV
Minerva Neurosciences
1.6614 of 5 stars
$6.55
-4.0%
$8.00
+22.1%
+86.6%$36.48M$41.18M-1.199Positive News
CKPT
Checkpoint Therapeutics
2.0445 of 5 stars
$2.82
-2.4%
$18.67
+561.9%
-81.4%$36.52M$190,000.000.0014Analyst Report
Gap Down
FLGC
Flora Growth
2.3312 of 5 stars
$0.24
flat
$2.00
+736.5%
-76.5%$32.81M$37.17M0.00N/APositive News
Gap Up
YMTX
Yumanity Therapeutics
0 of 5 stars
$3.02
-4.1%
N/A+183.0%$32.79M$4.84M-1.0140
NLTX
Neoleukin Therapeutics
2.3188 of 5 stars
$0.88
-2.2%
$5.88
+567.6%
-20.0%$37.69MN/A-0.8691

Related Companies and Tools

This page (NASDAQ:ORGS) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -